Ivan Gentile
Overview
Explore the profile of Ivan Gentile including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
2388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Micheletto C, Aliberti S, Andreoni M, Blasi F, Di Marco F, Di Matteo R, et al.
Respiration
. 2025 Mar;
:1-28.
PMID: 40058339
Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis, are significant global health concerns associated with recurrent exacerbations, hospitalization, and increased mortality. Preventive strategies, particularly vaccination, play a...
2.
Gentile I, Giuliano S, Corcione S, De Rosa F, Falcone M, Giacobbe D, et al.
Expert Rev Anti Infect Ther
. 2025 Jan;
:1-9.
PMID: 39882832
Introduction: Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness...
3.
Zarkadoulas E, Comparoni S, Freguja R, Santacroce R, Dovizio M, Veronesi C, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae738.
PMID: 39877401
Background: Risk of herpes zoster (HZ) infection increases with age and immunosuppression. We estimated the impact of HZ and post-herpetic neuralgia (PHN) on direct costs and health care resource utilization...
4.
Membrillo de Novales F, Falcone M, Soriano A, Fernandez-Hidalgo N, Francisci D, Gentile I, et al.
Int J Antimicrob Agents
. 2025 Jan;
65(4):107450.
PMID: 39864599
Background And Aim: Ceftobiprole, an advanced-generation cephalosporin with broad bactericidal activity, is approved for community-acquired and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). We aimed to evaluate, in a real-world setting, the...
5.
Gentile I, Giaccone A, Scirocco M, Di Brizzi F, Cuccurullo F, Silvitelli M, et al.
BMC Infect Dis
. 2024 Dec;
24(1):1434.
PMID: 39696011
Background: Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral protease, administered to prevent the progression of SARS-CoV-2 infection in patients at high risk for severe COVID-19. We...
6.
Tiseo G, Galfo V, Carbonara S, Marino A, Di Caprio G, Carretta A, et al.
Infection
. 2024 Dec;
PMID: 39643843
Purpose: To describe the clinical characteristics and outcomes of patients with nosocomial pneumonia (NP) caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) and to compare them to patients with NP caused by...
7.
Pinchera B, Trucillo E, DAgostino A, Gentile I
Microorganisms
. 2024 Nov;
12(11).
PMID: 39597604
Urinary tract infections are one of the main complications in kidney transplant patients, with a significant impact on graft function and survival. In fact, it is estimated that up to...
8.
Buonomo A, Scotto R, Esposito N, Viceconte G, Schiano Moriello N, Zumbo G, et al.
Antibiotics (Basel)
. 2024 Nov;
13(11).
PMID: 39596702
Carbapenem-resistant (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. We enrolled 45 patients. Cefiderocol was administered to 40% of...
9.
Pinchera B, Carrano R, Salemi F, Piccione A, Schettino E, Cuccurullo F, et al.
Exp Clin Transplant
. 2024 Nov;
22(10):810-813.
PMID: 39588997
Objectives: Hepatitis delta virus infection poses a significant challenge in solid-organ transplant recipients due to its aggressive nature and limited therapeutic options. Bulevirtide is a novel antiviral agent approved by...
10.
Pinchera B, Carrano R, Salemi F, Piccione A, Schettino E, Romano P, et al.
New Microbiol
. 2024 Nov;
47(3):265-268.
PMID: 39560038
Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in immunocompromised patients has reduced the risk of breakthrough infection, disease, hospitalization, and COVID-19 related mortality. However, the advent of the Kraken variant (XBB.1.5)...